Corient Private Wealth LLC Acquires 34,354 Shares of Moderna, Inc. $MRNA

Corient Private Wealth LLC increased its position in Moderna, Inc. (NASDAQ:MRNA) by 155.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 56,400 shares of the company’s stock after purchasing an additional 34,354 shares during the quarter. Corient Private Wealth LLC’s holdings in Moderna were worth $1,537,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Parkside Financial Bank & Trust lifted its stake in Moderna by 19.0% during the 2nd quarter. Parkside Financial Bank & Trust now owns 2,347 shares of the company’s stock valued at $65,000 after acquiring an additional 375 shares in the last quarter. Probity Advisors Inc. increased its position in Moderna by 2.6% in the second quarter. Probity Advisors Inc. now owns 14,892 shares of the company’s stock worth $411,000 after buying an additional 377 shares during the last quarter. Amalgamated Bank increased its holdings in Moderna by 0.6% in the 2nd quarter. Amalgamated Bank now owns 65,458 shares of the company’s stock worth $1,806,000 after acquiring an additional 408 shares during the last quarter. Rothschild Investment LLC lifted its stake in shares of Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after buying an additional 446 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV grew its position in shares of Moderna by 1.4% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 40,639 shares of the company’s stock valued at $1,152,000 after purchasing an additional 562 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director directly owned 3,924 shares in the company, valued at approximately $115,679.52. The trade was a 85.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 10.90% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $32.73 on Thursday. The stock’s fifty day moving average is $26.78 and its 200 day moving average is $27.33. The firm has a market capitalization of $12.79 billion, a PE ratio of -4.06 and a beta of 1.11. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $48.92.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.Moderna’s revenue was down 45.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 EPS. Equities analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on MRNA. Morgan Stanley decreased their price target on shares of Moderna from $30.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moderna in a research note on Wednesday, October 8th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Monday, October 20th. Jefferies Financial Group initiated coverage on shares of Moderna in a research report on Friday, December 12th. They issued a “hold” rating and a $30.00 price objective on the stock. Finally, Berenberg Bank set a $28.00 target price on Moderna in a report on Monday, November 17th. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the company’s stock. According to data from MarketBeat, Moderna currently has an average rating of “Reduce” and an average target price of $29.21.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.